A review of the impact of patch testing on quality of life in allergic contact dermatitis

Ramirez, Faustine D.; Chren, Mary‐Margaret; Botto, Nina

doi:10.1016/j.jaad.2016.12.011

Cited by 20 publications

(14 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, currently, only data from two ACD-specific QoL tools exist, one of which only assessed patients with fragrance allergies and one that was used solely on a population of Italian patients without validation data. A review of the literature suggests that more general skin QoL tools may not pick up on the specific impacts ACD has on patients’ experience [10]. Therefore, asking patients for their own assessments of global improvement or worsening without using a validated tool can provide important insight into patient benefit and improvement [2], especially as an exploratory study before developing a validated ACD-specific QoL tool looking at patch test patients in this country.…”

Section: Introductionmentioning

confidence: 99%

Patient Reported Improvement After Patch Testing and Allergen Avoidance Counseling: A Retrospective Analysis

Steuer

Botto

2018

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

IntroductionOur objectives were to assess patient-reported improvement after patch testing at the 2–3-month follow-up visit in patients referred for patch testing with relevant positive patch test reactions at the University of California, San Francisco.MethodsCross-sectional analyses of patients patch tested between 2013 and 2016 who returned for a follow-up visit approximately 2–3 months after patch testing. We examined positive patch test results considered of definite, probable or possible relevance to the patient’s eczematous eruptions. Patients reported improvement after patch testing as a percentage: 0–100%. Patients were categorized into four groups: (1) those that reported no improvement or worsened, (2) those that reported > 0% and ≤ 60% improvement, (3) those that reported > 60% but < 100% improvement and (4) those that reported 100% improvement. Secondary measures included the association of allergens, gender, age and location of the rash.ResultsThe majority (81%) of patients seen at follow-up reported improvement after patch testing. Women reported more improvement than men with statistical significance. Notably, there does not appear to be a statistically significant relationship in patient-reported improvement and age, atopy, strength of a the patient’s positive reactions, number of positive reactions and follow-up time or with potential systemic contact allergens (i.e., balsam of Peru, nickel, chrome and cobalt).ConclusionWe find the large percentage of patients that self-report global benefit from patch testing encouraging, as we believe this to be a powerful measure of disease and symptom activity, as well as quality of life. The gender differences we found contradict the previous literature.

show abstract

Section: Introductionmentioning

confidence: 99%

Patient Reported Improvement After Patch Testing and Allergen Avoidance Counseling: A Retrospective Analysis

Steuer

Botto

2018

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

show abstract

“…The instruments available to assess the burden of ACD on the HRQoL of patients are questionnaires that range from generic to disease-specific [ 37 , 45 , 48 – 52 ]. The most commonly used dermatology-specific QoL questionnaires in patients with ACD are the DLQI [ 39 , 53 , 54 ], the Skindex-29 or Skindex-16 [ 32 , 33 , 43 , 55 ], and the DSQL [ 9 , 56 ].…”

Section: Main Textmentioning

confidence: 99%

Quality of life in patients with allergic and immunologic skin diseases: in the eye of the beholder

et al. 2021

View full text Add to dashboard Cite

Allergic and immunologic skin diseases negatively impact the quality of life (QoL) of affected patients with detrimental consequences. Nonetheless, in everyday clinical practice the evaluation of QoL is often overlooked. Considering the increasing prevalence of atopic dermatitis, allergic contact dermatitis, hereditary angioedema, cutaneous mastocytosis, and urticaria, it is essential to determine the effects of allergic and immunologic skin diseases on QoL. A joint meeting (GET TOGETHER 2021) of the Italian Society of Allergology, Asthma and Clinical Immunology (SIAAIC) and the Italian Society of Allergological, Occupational and Environmental Dermatology (SIDAPA) aimed to summarize the features of the main QoL tools used in these diseases and to describe the extent of QoL impairment as well as the impact of treatments on QoL, particularly biologic therapies. The assessment of QoL in patients with allergic and immunologic skin diseases relies on generic, organ-specific and disease-specific questionnaires. While generic and organ-specific questionnaires allow comparison between different diseases, disease-specific questionnaires are designed and validated for specific cohorts: the QoL Index for Atopic Dermatitis (QoLIAD) and the Childhood Atopic Dermatitis Impact Scale (CADIS) in atopic dermatitis, the ACD-11 in allergic contact dermatitis, the Angioedema QoL Questionnaire (AE-QoL) and the Hereditary Angioedema QoL questionnaire (HAE-QoL) in hereditary angioedema, the Mastocytosis QoL Questionnaires (MCQoL e MQLQ) in cutaneous mastocytosis, and the Chronic Urticaria QoL questionnaire (CU-Q2oL) in urticaria. Among the many factors that variably contribute to QoL impairment, pruritus can represent the leading cause of patient discomfort. Biologic therapies significantly ameliorate QoL in atopic dermatitis, hereditary angioedema, mastocytosis and chronic urticaria. In general, adequate management strategies are essential for improving QoL in patients with allergic and immunologic skin diseases.

show abstract

“…Furthermore, patients with positive patch test results showed greater improvement in HRQoL compared with non‐patch‐tested patients and patients with negative patch tests results 26–29 . A review article on the impact of patch testing on QoL in allergic contact dermatitis also concluded that patch testing leads to QoL improvement 30 . Patch testing helps to diagnose the aetiology of allergic contact dermatitis and hence provide targeted avoidance strategy and effective management.…”

Section: Management Approaches That May Improve Qol In Dermatologymentioning

confidence: 99%

Methods to improve quality of life, beyond medicines. Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes

Finlay

Chernyshov

Aragonés

et al. 2020

Acad Dermatol Venereol

View full text Add to dashboard Cite

The pharmaceutical approach to skin disease has been hugely successful, but despite effective drugs being available and used, there are still vast numbers of people who continue to have some level of persisting skin disease and continue to experience quality of life (QoL) impairment. So the question that needs to be answered, while we await further advances in our drug‐based armamentarium, is how can we improve patients’ QoL, beyond drugs? A working group was formed from members of the EADV Task Force on QoL and Patient Oriented Outcomes. Participants were asked to suggest all the ways in which they considered patients’ QoL may be improved beyond medicines. Four groups of management approaches that may improve QoL in dermatology were identified: interventions within the dermatology service (hospitalization, multidisciplinary teams, patch testing and establishing relevant allergens and education), external services (corrective make‐up, climatotherapy and balneotherapy), psychological (psychological intervention, cognitive therapy, hypnosis), lifestyle (lifestyle behavioural changes, religion and spirituality and music). The ultimate aim of therapy is to eradicate a disease in an individual and return the person’s life to normal. But until the day comes when this has been achieved for every skin disease and for every patient there will be a need to support and assist many patients in additional non‐pharmaceutical ways. These ‘adjuvant’ approaches receive too little attention while dermatologists and researchers strive for better pharmacological therapy. The different ways in which patients may benefit have been reviewed in our paper, but the reality is that most have a very poor evidence base. The research challenges that we have to meet are to identify those approaches that might be of value and to provide evidence for their optimal use. In the meantime, clinicians should consider the use of these approaches where QoL remains impaired despite optimal use of standard therapy.

show abstract

A review of the impact of patch testing on quality of life in allergic contact dermatitis

Cited by 20 publications

References 4 publications

Patient Reported Improvement After Patch Testing and Allergen Avoidance Counseling: A Retrospective Analysis

Patient Reported Improvement After Patch Testing and Allergen Avoidance Counseling: A Retrospective Analysis

Quality of life in patients with allergic and immunologic skin diseases: in the eye of the beholder

Methods to improve quality of life, beyond medicines. Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes

Contact Info

Product

Resources

About